Maternal screen (Triple marker test) Second trimester50+ booked in last 3 days
Triple Marker Test (Also called triple screen)
Frequently Asked Questions
Triple marker tests identify pregnancies that have a high risk of babies having the following abnormalities:
- Trisomy 21 (Down’s syndrome)
- Trisomy 18 (Edward syndrome)
- Neural tube defects
These tests are NOT diagnostic tests. Your doctor will order a confirmatory test when the screening test is positive (high risk)
This test is conducted between the 14th and 18th weeks of pregnancy.
The test is often most recommended under the following scenarios
- Age of the pregnant woman is above 35
- Dual Marker tests were abnormal
- Birth defects in the family
- The pregnant woman is diabetic and under insulin medication
- If it is suspected that the pregnant woman was exposed to a high dose of radiation
- A viral infection during pregnancy
AFP (Alpha-fetoprotein) AFP or alpha fetoprotein is made by the foetal liver and some amount of this substance gets into the mother’s blood. Higher levels of AFP are seen in Neural tube defects and levels are decreased in Down syndrome and Edward syndrome. What if I am a man and have high AFP level? What if I am a non-pregnant woman and have high AFP level? In men, non-pregnant women, and children, AFP in the blood can mean certain types of cancer, especially cancer of the testicles, ovaries, stomach, pancreas, or liver are present. uE3 (Unconjugated Estriol) Estriol is a hormone produced by the placenta, using ingredients made by the fetal liver and adrenal glands. In pregnancies with Down Syndrome or Edward Syndrome, it is observed that the Estriol levels are reduced.
Ratings & Reviews (0)
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.